✦ LIBER ✦

Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo

✍ Scribed by KLAS NORRBY; ARVID NORDENHEM

Book ID: 109344071
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 100 KB
Volume: 118
Category: Article
ISSN: 0365-5555
DOI: 10.1111/j.1600-0463.2010.02635.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effect of low molecular weight heparin (

Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra®) on human osteoblasts in vitro

✍ A. E. Handschin; O. A. Trentz; S. P. Hoerstrup; H. J. Kock; G. A. Wanner; O. Tre 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB 👁 2 views

Low molecular weight protamine as nontox

Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): Preliminary in vivo evaluation of efficacy and toxicity using a canine model

✍ Chang, Li-Chien ;Wrobleski, Shirley ;Wakefield, Thomas W. ;Lee, Lai Ming ;Yang, 📂 Article 📅 2001 🏛 Springer US 🌐 English ⚖ 388 KB

The low-molecular-weight heparin, nadrop

The low-molecular-weight heparin, nadroparin, inhibits tumour angiogenesis in a rodent dorsal skinfold chamber model

✍ Debergh, I; Van Damme, N; Pattyn, P; Peeters, M; Ceelen, W P 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 589 KB

PRODIGE: a randomized placebo-controlled

PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma

✍ J. R. PERRY; J. A. JULIAN; N. J. LAPERRIERE; W. GEERTS; G. AGNELLI; L. R. ROGERS 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 307 KB

Polyproline-type helical-structured low-

Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor

✍ Esak Lee; Yoo-Shin Kim; Sang Mun Bae; Sang Kyoon Kim; Shunji Jin; Seung Woo Chun 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 721 KB

## Abstract Although heparin can regulate angiogenesis, tumor growth and metastasis, its clinical application, as well as that of low‐molecular heparin (LMWH), for treating cancer are limited because of heparin's anticoagulant activity and risk of hemorrhages. LMWH‐taurocholate conjugates (LHT7), w

A pilot study on systemic thrombolysis f

A pilot study on systemic thrombolysis followed by low molecular weight heparin in ischemic stroke

✍ R. Mikulík; M. Dufek; D. Goldemund; M. Reif 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 468 KB